Edwards Lifesciences Corp (EW) is a leading medical devices business with stocks listed in the US. It opened the day at US$85.6 after a previous close of US$85.09. During the day the price has varied from a low of USD85.01 to a high of USD86.19. The latest price was USD85.84 (25 minute delay). Edwards Lifesciences is listed on the NYSE. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
Best for beginner
Our top pick for
Dividend investing
Edwards Lifesciences's shares were split on a 3:1 basis on 31 May 2020. So if you had owned 1 share the day before the split, the next day you would own 3 shares. This wouldn't directly have changed the overall worth of your Edwards Lifesciences shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Edwards Lifesciences shares which in turn could have impacted Edwards Lifesciences's share price.
| Open | US$85.6 |
|---|---|
| High | US$86.19 |
| Low | US$85.01 |
| Close | US$85.84 |
| Previous close | US$85.09 |
| Change | US$0.75 |
| Change % | 0.8814% |
| Volume | 1,814,456 |
| 52-week range | US$60.57 - US$96.12 |
|---|---|
| 50-day moving average | US$90.0018 |
| 200-day moving average | US$78.533 |
| Target price | US$95.48 |
| PE ratio | 36.6638 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$2.32 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $85.84
| 1 week (2024-05-01) | 1.83% |
|---|---|
| 1 month (2024-04-08) | -7.04% |
| 3 months (2024-02-08) | 0.05% |
| 6 months (2023-11-08) | 29.59% |
| 1 year (2023-05-05) | -3.27% |
|---|---|
| 2 years (2022-05-06) | -14.60% |
| 3 years (2021-05-07) | -6.87% |
| 5 years (2019-05-08) | 44.86% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Edwards Lifesciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Edwards Lifesciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Edwards Lifesciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, Edwards Lifesciences shares trade at around 37x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Edwards Lifesciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.1879. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Edwards Lifesciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Edwards Lifesciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$1.9 billion (£1.5 billion).
The EBITDA is a measure of a Edwards Lifesciences's overall financial performance and is widely used to measure stock profitability.
Over the last 12 months, Edwards Lifesciences's shares have ranged in value from as little as US$60.57 up to US$96.12. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Edwards Lifesciences's is 1.074. This would suggest that Edwards Lifesciences's shares are a little bit more volatile than the average for this exchange and represent, relatively speaking, a slightly higher risk (but potentially also market-beating returns).
| Revenue TTM | US$6.1 billion |
|---|---|
| Operating margin TTM | 27.39% |
| Gross profit TTM | US$4.3 billion |
| Return on assets TTM | 12.05% |
| Return on equity TTM | 21.28% |
| Profit margin | 23.01% |
| Book value | 11.816 |
| Market capitalisation | US$51.3 billion |
TTM: trailing 12 months
We're not expecting Edwards Lifesciences to pay a dividend over the next 12 months.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Edwards Lifesciences.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 21.68
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Edwards Lifesciences's overall score of 21.68 (as at 12/31/2018) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Edwards Lifesciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.78/100
Edwards Lifesciences's environmental score of 4.78 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 13.43/100
Edwards Lifesciences's social score of 13.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 10.96/100
Edwards Lifesciences's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Edwards Lifesciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Edwards Lifesciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Edwards Lifesciences has, for the most part, managed to keep its nose clean.
Edwards Lifesciences Corp was last rated for ESG on: 2019-01-01.
| Total ESG score | 21.68 |
|---|---|
| Total ESG percentile | 24.1 |
| Environmental score | 4.78 |
| Environmental score percentile | 6 |
| Social score | 13.43 |
| Social score percentile | 6 |
| Governance score | 10.96 |
| Governance score percentile | 6 |
| Level of controversy | 2 |
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Steps to owning and managing Tasmea Limited shares.
Your in-depth review of the Bendigo Invest Direct share trading service and what it offers for Aussie investors.
Here are our algorithm-selected 20 Aussie stocks worth watching in 2024.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Following a couple of lean years for dividend investors, here are 20 ideas you could consider in your portfolio.
Earn interest on your cash balance and enjoy competitive brokerage fees from just $6 with Interactive Brokers.
SelfWealth online share trading provides easy access to the Australian share market with a flat brokerage fee per trade, no matter the size.
GO Markets offers a comprehensive package to both share investors and experienced CFD traders.
With amscot, you get to trade in shares using an online platform or over the phone, while paying competitive fees. Learn more in our amscot review.
Bell Direct offers one-second placement guarantees for trades, so you can take advantage of all trading opportunities at the price you want.